Altered production of brain-derived neurotrophic factor by peripheral blood immune cells in multiple sclerosis

Satoshi Yoshimura, Hirofumi Ochi, Noriko Isobe, Takuya Matsushita, Kyoko Motomura, Takeshi Matsuoka, Motozumi Minohara, Jun-Ichi Kira

研究成果: ジャーナルへの寄稿記事

16 引用 (Scopus)

抄録

Background: Within multiple sclerosis lesions, brain-derived neurotrophic factor is detected in neurons and immunocytes. Objective: To clarify brain-derived neurotrophic factor production by peripheral blood immunocytes and its relationship with clinical parameters in multiple sclerosis. Methods: Serum brain-derived neurotrophic factor levels were measured by conventional enzyme-linked immunosorbent assay while brain-derived neurotrophic factor production by immunocytes was determined by an in situ enzyme-linked immunosorbent assay in 74 multiple sclerosis patients, 32 healthy controls, and 86 patients with other neurological diseases. The tyrosine kinase receptor TrkB expression level in peripheral blood mononuclear cells was measured by real-time polymerase chain reaction. Results: Multiple sclerosis patients showed significantly higher serum brain-derived neurotrophic factor levels than healthy controls and patients with other neurological diseases. Multiple sclerosis patients with high brain-derived neurotrophic factor levels were younger, and showed fewer relapse numbers than those with low brain-derived neurotrophic factor levels. Brain-derived neurotrophic factor production by T cells increased with age in healthy controls, but not in multiple sclerosis patients. Interferon beta induced a significant increase in serum brain-derived neurotrophic factor levels. Brain-derived neurotrophic factor production from T cells and TrkB expression levels in peripheral blood mononuclear cells were significantly enhanced in interferon beta-treated multiple sclerosis patients compared with untreated ones. Conclusions: A high brain-derived neurotrophic factor level is related to early mild disease in young multiple sclerosis patients. Interferon beta potentiates brain-derived neurotrophic factor production and brain-derived neurotrophic factor receptor expression in peripheral blood mononuclear cells, which may act beneficially.

元の言語英語
ページ(範囲)1178-1188
ページ数11
ジャーナルMultiple Sclerosis
16
発行部数10
DOI
出版物ステータス出版済み - 10 1 2010

Fingerprint

Brain-Derived Neurotrophic Factor
Multiple Sclerosis
Blood Cells
Interferon-beta
Serum
Enzyme-Linked Immunosorbent Assay
trkB Receptor
T-Lymphocytes
Receptor Protein-Tyrosine Kinases
Real-Time Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Neurology

これを引用

Altered production of brain-derived neurotrophic factor by peripheral blood immune cells in multiple sclerosis. / Yoshimura, Satoshi; Ochi, Hirofumi; Isobe, Noriko; Matsushita, Takuya; Motomura, Kyoko; Matsuoka, Takeshi; Minohara, Motozumi; Kira, Jun-Ichi.

:: Multiple Sclerosis, 巻 16, 番号 10, 01.10.2010, p. 1178-1188.

研究成果: ジャーナルへの寄稿記事

Yoshimura, Satoshi ; Ochi, Hirofumi ; Isobe, Noriko ; Matsushita, Takuya ; Motomura, Kyoko ; Matsuoka, Takeshi ; Minohara, Motozumi ; Kira, Jun-Ichi. / Altered production of brain-derived neurotrophic factor by peripheral blood immune cells in multiple sclerosis. :: Multiple Sclerosis. 2010 ; 巻 16, 番号 10. pp. 1178-1188.
@article{4198a9acb94e4fe09e3d7c7468903180,
title = "Altered production of brain-derived neurotrophic factor by peripheral blood immune cells in multiple sclerosis",
abstract = "Background: Within multiple sclerosis lesions, brain-derived neurotrophic factor is detected in neurons and immunocytes. Objective: To clarify brain-derived neurotrophic factor production by peripheral blood immunocytes and its relationship with clinical parameters in multiple sclerosis. Methods: Serum brain-derived neurotrophic factor levels were measured by conventional enzyme-linked immunosorbent assay while brain-derived neurotrophic factor production by immunocytes was determined by an in situ enzyme-linked immunosorbent assay in 74 multiple sclerosis patients, 32 healthy controls, and 86 patients with other neurological diseases. The tyrosine kinase receptor TrkB expression level in peripheral blood mononuclear cells was measured by real-time polymerase chain reaction. Results: Multiple sclerosis patients showed significantly higher serum brain-derived neurotrophic factor levels than healthy controls and patients with other neurological diseases. Multiple sclerosis patients with high brain-derived neurotrophic factor levels were younger, and showed fewer relapse numbers than those with low brain-derived neurotrophic factor levels. Brain-derived neurotrophic factor production by T cells increased with age in healthy controls, but not in multiple sclerosis patients. Interferon beta induced a significant increase in serum brain-derived neurotrophic factor levels. Brain-derived neurotrophic factor production from T cells and TrkB expression levels in peripheral blood mononuclear cells were significantly enhanced in interferon beta-treated multiple sclerosis patients compared with untreated ones. Conclusions: A high brain-derived neurotrophic factor level is related to early mild disease in young multiple sclerosis patients. Interferon beta potentiates brain-derived neurotrophic factor production and brain-derived neurotrophic factor receptor expression in peripheral blood mononuclear cells, which may act beneficially.",
author = "Satoshi Yoshimura and Hirofumi Ochi and Noriko Isobe and Takuya Matsushita and Kyoko Motomura and Takeshi Matsuoka and Motozumi Minohara and Jun-Ichi Kira",
year = "2010",
month = "10",
day = "1",
doi = "10.1177/1352458510375706",
language = "English",
volume = "16",
pages = "1178--1188",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "10",

}

TY - JOUR

T1 - Altered production of brain-derived neurotrophic factor by peripheral blood immune cells in multiple sclerosis

AU - Yoshimura, Satoshi

AU - Ochi, Hirofumi

AU - Isobe, Noriko

AU - Matsushita, Takuya

AU - Motomura, Kyoko

AU - Matsuoka, Takeshi

AU - Minohara, Motozumi

AU - Kira, Jun-Ichi

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Background: Within multiple sclerosis lesions, brain-derived neurotrophic factor is detected in neurons and immunocytes. Objective: To clarify brain-derived neurotrophic factor production by peripheral blood immunocytes and its relationship with clinical parameters in multiple sclerosis. Methods: Serum brain-derived neurotrophic factor levels were measured by conventional enzyme-linked immunosorbent assay while brain-derived neurotrophic factor production by immunocytes was determined by an in situ enzyme-linked immunosorbent assay in 74 multiple sclerosis patients, 32 healthy controls, and 86 patients with other neurological diseases. The tyrosine kinase receptor TrkB expression level in peripheral blood mononuclear cells was measured by real-time polymerase chain reaction. Results: Multiple sclerosis patients showed significantly higher serum brain-derived neurotrophic factor levels than healthy controls and patients with other neurological diseases. Multiple sclerosis patients with high brain-derived neurotrophic factor levels were younger, and showed fewer relapse numbers than those with low brain-derived neurotrophic factor levels. Brain-derived neurotrophic factor production by T cells increased with age in healthy controls, but not in multiple sclerosis patients. Interferon beta induced a significant increase in serum brain-derived neurotrophic factor levels. Brain-derived neurotrophic factor production from T cells and TrkB expression levels in peripheral blood mononuclear cells were significantly enhanced in interferon beta-treated multiple sclerosis patients compared with untreated ones. Conclusions: A high brain-derived neurotrophic factor level is related to early mild disease in young multiple sclerosis patients. Interferon beta potentiates brain-derived neurotrophic factor production and brain-derived neurotrophic factor receptor expression in peripheral blood mononuclear cells, which may act beneficially.

AB - Background: Within multiple sclerosis lesions, brain-derived neurotrophic factor is detected in neurons and immunocytes. Objective: To clarify brain-derived neurotrophic factor production by peripheral blood immunocytes and its relationship with clinical parameters in multiple sclerosis. Methods: Serum brain-derived neurotrophic factor levels were measured by conventional enzyme-linked immunosorbent assay while brain-derived neurotrophic factor production by immunocytes was determined by an in situ enzyme-linked immunosorbent assay in 74 multiple sclerosis patients, 32 healthy controls, and 86 patients with other neurological diseases. The tyrosine kinase receptor TrkB expression level in peripheral blood mononuclear cells was measured by real-time polymerase chain reaction. Results: Multiple sclerosis patients showed significantly higher serum brain-derived neurotrophic factor levels than healthy controls and patients with other neurological diseases. Multiple sclerosis patients with high brain-derived neurotrophic factor levels were younger, and showed fewer relapse numbers than those with low brain-derived neurotrophic factor levels. Brain-derived neurotrophic factor production by T cells increased with age in healthy controls, but not in multiple sclerosis patients. Interferon beta induced a significant increase in serum brain-derived neurotrophic factor levels. Brain-derived neurotrophic factor production from T cells and TrkB expression levels in peripheral blood mononuclear cells were significantly enhanced in interferon beta-treated multiple sclerosis patients compared with untreated ones. Conclusions: A high brain-derived neurotrophic factor level is related to early mild disease in young multiple sclerosis patients. Interferon beta potentiates brain-derived neurotrophic factor production and brain-derived neurotrophic factor receptor expression in peripheral blood mononuclear cells, which may act beneficially.

UR - http://www.scopus.com/inward/record.url?scp=77957607357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957607357&partnerID=8YFLogxK

U2 - 10.1177/1352458510375706

DO - 10.1177/1352458510375706

M3 - Article

C2 - 20656764

AN - SCOPUS:77957607357

VL - 16

SP - 1178

EP - 1188

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 10

ER -